Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $59.94 million for the quarter.

Aurinia Pharmaceuticals Trading Up 2.6 %

Shares of NASDAQ AUPH opened at $7.99 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $10.67. The firm has a 50 day moving average price of $8.47 and a two-hundred day moving average price of $7.66. The stock has a market cap of $1.14 billion, a P/E ratio of -53.26 and a beta of 1.22.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 10th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.